Respiratory

Alpha-1 antitrypsin deficiency: pulmonary and hepatic presentation

Clinical Overview and When to Suspect Alpha-1 Antitrypsin Deficiency

— Pathologic alleles: PiZ (most common severe), PiS (mild), null variants

— PiMM = normal; PiMZ = carrier (mild risk); PiSZ = intermediate; PiZZ = classic severe phenotype (~10–15% serum levels)

— Lung: loss of antiprotease activity → unopposed elastase → panacinar emphysema, lower-lobe predominant

— Liver: misfolded Z protein polymerizes and accumulates in hepatocyte ER → PAS-positive, diastase-resistant globules, hepatitis, cirrhosis, HCC

— COPD/emphysema before age 45, especially nonsmoker or minimal smoking

— Emphysema with basilar (lower-lobe) predominance on CT

— Unexplained chronic liver disease in adults or neonatal cholestasis/jaundice persisting >2 weeks

— Family history of early COPD, cirrhosis, or known AAT deficiency

— Adult-onset asthma with incompletely reversible airflow obstruction

— Necrotizing panniculitis or C-ANCA/PR3 vasculitis (granulomatosis with polyangiitis association)

Alpha-1 antitrypsin (AAT) deficiency is an autosomal codominant disorder of the SERPINA1 gene on chromosome 14 producing a defective serine protease inhibitor that normally neutralizes neutrophil elastase in the lung and folds properly in hepatocytes

Dual-organ disease driven by two mechanisms:

When to suspect on Step 3:

Epidemiology: prevalence ~1:3,000–5,000 in US whites of Northern European descent; vastly underdiagnosed (mean delay 5–7 years from symptom onset)

Board pearl: The GOLD and ATS/ERS guidelines recommend testing all symptomatic adults with COPD, poorly controlled asthma, cryptogenic cirrhosis, or unexplained bronchiectasis for AAT deficiency at least once—a one-time screen is the right answer on Step 3 stems showing early or atypical emphysema

Smoking accelerates lung disease by decades; counseling is the single most impactful intervention

Presentation Patterns and Key History

— Progressive dyspnea on exertion, chronic cough, wheeze, sputum production

— Onset typically 30s–50s, far earlier than tobacco-only COPD

— Recurrent bronchitis or pneumonia, sometimes labeled "refractory asthma"

— Bronchiectasis in ~25–40% on high-resolution CT

— Neonates: prolonged conjugated hyperbilirubinemia, hepatomegaly, acholic stools (mimics biliary atresia) — most resolve, but ~10–20% progress

— Children/adolescents: elevated transaminases, occasionally cirrhosis

— Adults: cryptogenic cirrhosis, portal hypertension, hepatocellular carcinoma (risk elevated independent of cirrhosis)

— Liver disease occurs almost exclusively in PiZZ (and rare null/null with retained protein); PiSS does not cause liver disease because S protein does not polymerize

— Necrotizing panniculitis: painful, ulcerating subcutaneous nodules on trunk/thighs

— C-ANCA (PR3) vasculitis / granulomatosis with polyangiitis association

— Glomerulonephritis (rare)

— Pack-year history (often low or zero)

— Family history of COPD, cirrhosis, HCC, liver transplant

— Occupational dust/fume exposure (synergistic risk)

— Neonatal jaundice history

— Ethnic background (Northern European descent ↑ risk)

Pulmonary presentation (most common adult phenotype):

Hepatic presentation:

Extrapulmonary/extrahepatic clues:

Key history questions on a Step 3 stem:

Key distinction: A 40-year-old never-smoker with basal emphysema points to AAT deficiency; a 65-year-old 50-pack-year smoker with apical emphysema points to typical tobacco COPD. The age + smoking burden + lobe distribution triad is the Step 3 fingerprint

Step 3 management: Even after a single suggestive history, order serum AAT level + phenotype (or genotype) at the index visit—do not defer to pulmonology for the screening test itself

Physical Exam Findings and Hemodynamic Assessment

— Barrel chest, increased AP diameter, hyperresonance to percussion

— Diminished breath sounds, prolonged expiratory phase, expiratory wheeze

— Accessory muscle use, pursed-lip breathing, tripoding

— Hoover sign: paradoxical inward movement of lower ribs on inspiration from flattened diaphragm

— Cyanosis and digital clubbing are uncommon—clubbing should prompt search for bronchiectasis, fibrosis, or malignancy

— Loud P2, right-sided S3/S4, parasternal heave

— Elevated JVP with prominent a-wave; later tricuspid regurgitation murmur (holosystolic, left lower sternal border, ↑ with inspiration — Carvallo sign)

— Hepatomegaly (passive congestion vs. intrinsic AAT liver disease — distinguish!)

— Peripheral edema, ascites

— Stigmata of chronic liver disease: spider angiomata, palmar erythema, gynecomastia, caput medusae, splenomegaly, asterixis

— Firm, nodular liver edge in cirrhosis; hepatomegaly with mass raises HCC concern

— Tender, erythematous, sometimes ulcerating nodules of necrotizing panniculitis drain oily/serosanguinous fluid

— Resting SpO₂ may be preserved until advanced disease; check ambulatory/exertional SpO₂

— Resting tachycardia and pulsus paradoxus suggest decompensation

Pulmonary exam (advanced disease):

Cardiovascular/hemodynamic findings as disease progresses to cor pulmonale:

Hepatic exam:

Skin:

Vital sign and oximetry pearls:

Board pearl: Hepatomegaly in an AAT patient can be dual-etiology—right heart failure from cor pulmonale plus intrinsic AAT liver disease. Don't anchor; order echocardiogram + liver ultrasound with elastography to disentangle

CCS pearl: Document pulse oximetry at rest AND with 6-minute walk; ambulatory desaturation to <88% qualifies the patient for long-term oxygen therapy and changes management orders

Diagnostic Workup — Initial Labs, Imaging, PFTs, Biomarkers

— Serum AAT level by nephelometry; normal 100–200 mg/dL (or 20–48 µmol/L)

— Severe deficiency typically <57 mg/dL (<11 µmol/L)

— Caveat: AAT is an acute-phase reactant—levels rise with infection/inflammation and can mask deficiency. Pair with CRP or repeat when stable; always proceed to phenotype/genotype if clinical suspicion is high regardless of level

— Phenotyping (isoelectric focusing) identifies Pi variants (M, S, Z, null)

— Genotyping (PCR) for common alleles; gene sequencing for rare/null variants when phenotype-genotype discordant

— Obstructive pattern: FEV1/FVC < 0.70 (post-bronchodilator), reduced FEV1

— ↓ DLCO (emphysema hallmark)

— Increased TLC, RV, RV/TLC ratio (air trapping/hyperinflation)

— Minimal bronchodilator reversibility (distinguishes from asthma)

— CXR: hyperinflation, flattened diaphragms, increased retrosternal airspace

— HRCT chest: panacinar emphysema with lower-lobe (basilar) predominance—the imaging signature; bronchiectasis in subset

— AST, ALT, alkaline phosphatase, GGT, bilirubin, INR, albumin, platelets

— Hepatitis B/C serologies, iron studies, ceruloplasmin, ANA, anti-smooth muscle antibody (rule out co-existing liver disease)

— Liver ultrasound with elastography (FibroScan) for fibrosis staging

— AFP + ultrasound every 6 months if cirrhosis present (HCC surveillance)

Screening test (order first):

Confirmatory testing:

Pulmonary function tests:

Imaging:

Liver workup if AAT-deficient:

ABG in advanced disease: hypoxemia ± hypercapnia

Step 3 management: When AAT level is borderline (e.g., 80–100 mg/dL) and clinical suspicion remains, do not stop—reflex to phenotype. Borderline levels often reflect PiMZ or PiSZ heterozygotes who still warrant counseling

Diagnostic Workup — Advanced and Confirmatory Studies

— If serum level is low but genotype shows only MM, suspect a null allele → send full gene sequencing of SERPINA1

— Discordance also occurs with rare dysfunctional variants (e.g., PiMmalton, PiSiiyama)

— Indications: confirm cirrhosis when noninvasive testing equivocal, evaluate for competing etiologies, transplant evaluation

— Pathognomonic: PAS-positive, diastase-resistant cytoplasmic globules in periportal hepatocytes

— Elastography (FibroScan ≥ 10 kPa suggests advanced fibrosis) is replacing biopsy for staging

— 6-minute walk test: distance + ambulatory desaturation; baseline for rehab and oxygen qualification

— Cardiopulmonary exercise test in atypical dyspnea or pre-transplant

— Echocardiogram: estimate PASP, RV function for cor pulmonale assessment

— Right heart catheterization if pulmonary hypertension severe or out of proportion

— HRCT confirmation; sputum culture including AFB and fungi if recurrent infection

— Ultrasound ± AFP every 6 months in any AAT patient with cirrhosis, regardless of etiology contribution

— Test first-degree relatives (siblings, children) of probands—genetic counseling beforehand

— Identifies asymptomatic carriers who benefit from smoking avoidance counseling

Phenotype-genotype reconciliation:

Liver biopsy (selective):

Advanced pulmonary studies:

Bronchiectasis evaluation:

HCC surveillance:

Family screening:

Board pearl: A PAS-positive, diastase-resistant globule in a periportal hepatocyte is the single most testable histopathology buzzword for AAT deficiency on Step 3—pair it with cryptogenic cirrhosis stems

Key distinction: Phenotype (protein-based) is preferred when the patient may have recently received blood products or transplant; genotype is unaffected by transfusion. Choose accordingly on stems mentioning recent transfusion

Risk Stratification and First-Line Management Logic

— Smoking status is the dominant modifiable variable—every encounter, every patient

— FEV1 % predicted stratifies pulmonary severity (GOLD 1–4)

— Liver fibrosis stage (elastography/biopsy) stratifies hepatic risk

— Complete smoking cessation + avoidance of secondhand smoke and vaping

— Avoid occupational/environmental dusts, fumes, biomass smoke

— Vaccinations: annual influenza, pneumococcal (PCV20 or PCV15→PPSV23), COVID-19, RSV (age-appropriate), Tdap, hepatitis A and B (especially with liver disease)

— Alcohol cessation if any hepatic involvement

— Weight management; obesity worsens both NAFLD overlap and pulmonary mechanics

— Symptomatic + FEV1 30–65% predicted with non-/ex-smoker status → candidates for IV augmentation therapy

— GOLD-based inhaler stepwise therapy (LAMA → LAMA+LABA → triple therapy)

— Pulmonary rehab if mMRC ≥ 2 or recent exacerbation

— Long-term O₂ if PaO₂ ≤ 55 mmHg or SpO₂ ≤ 88% (or ≤ 59/89% with cor pulmonale/polycythemia)

— No specific medical therapy for AAT liver disease—augmentation does NOT treat liver disease (problem is intracellular accumulation, not deficiency)

— Treat portal hypertension complications per standard cirrhosis care

— Refer for liver transplant evaluation when MELD ≥ 15 or decompensation

Management hinges on organ involvement, severity, and modifiable risk factors:

Universal interventions for all AAT-deficient patients:

Pulmonary-specific stratification:

Hepatic-specific stratification:

Step 3 management: The single highest-yield intervention—more impactful than any drug—is smoking cessation counseling and pharmacotherapy (varenicline, bupropion, NRT). Always select it on stems offering it as an option, even alongside augmentation therapy

CCS pearl: Order vaccinations and smoking cessation at the initial visit; deferring to follow-up costs simulated time and points

Pharmacotherapy — First-Line Drug Regimen

— Products: pooled human plasma-derived alpha-1 proteinase inhibitor (Prolastin-C, Zemaira, Aralast NP, Glassia)

— Dose: 60 mg/kg IV once weekly (some regimens 120 mg/kg every 2 weeks)

— Goal: maintain trough serum AAT > 11 µmol/L (57 mg/dL) — the putative protective threshold

— Indications: PiZZ, null/null, or other severe-deficiency genotypes AND emphysema AND FEV1 typically 30–65% predicted (some guidelines extend 35–60%) AND non-smoker or ex-smoker

— Evidence: RAPID trial showed slowed CT-densitometry lung density loss; mortality benefit not definitively proven but standard of care in US

— Not indicated for: liver disease alone, MZ heterozygotes, current smokers, severe end-stage disease (FEV1 <30% without transplant plan—case-by-case)

— Group B (symptomatic, low exacerbation risk): LAMA + LABA

— Group E (≥2 exacerbations or hospitalization): LAMA + LABA + ICS (triple therapy), especially if eosinophils ≥ 300

— SABA (albuterol) PRN for all

— Roflumilast (PDE4 inhibitor) for severe COPD with chronic bronchitis and exacerbations

— Azithromycin 250 mg three times weekly for frequent exacerbators (screen QTc, hearing)

— Varenicline (first-line, most effective), bupropion SR, NRT (patch + short-acting combo)

IV AAT augmentation therapy (the disease-specific treatment):

Inhaled COPD therapy (GOLD-aligned):

Smoking cessation pharmacotherapy:

Liver disease: no targeted pharmacotherapy; investigational siRNA agents (fazirsiran) in trials—suppress Z-protein synthesis to reduce hepatic accumulation

Board pearl: Augmentation therapy is lifelong, IV, expensive (~$100K/year), and is the only AAT-specific drug. It addresses lung but not liver disease—a frequent Step 3 distractor. Know this dichotomy cold

Procedures and Advanced Interventions

— Surgical LVRS: generally not recommended in AAT-related emphysema because of lower-lobe predominance (NETT trial showed best outcomes in upper-lobe disease with low exercise capacity) — outcomes inferior compared to tobacco emphysema

— Endobronchial valves (Zephyr, Spiration): option for severe heterogeneous emphysema with intact fissures, even in AAT—careful patient selection by interventional pulmonology

— Indications: FEV1 < 25–30% predicted, hypercapnia, pulmonary hypertension, accelerated decline, BODE 7–10

— AAT patients typically receive transplant 5–10 years younger than tobacco COPD; outcomes comparable

— Augmentation continued peri-transplant is generally discontinued post-transplant (donor lungs make normal AAT)

— Curative for AAT liver disease—donor liver produces normal AAT protein, correcting both hepatic and (gradually) pulmonary deficiency

— Indications: decompensated cirrhosis, MELD ≥ 15, HCC within Milan criteria, intractable complications

— Pediatric AAT cirrhosis is a leading indication for pediatric liver transplant

— Variceal screening EGD at cirrhosis diagnosis; band ligation for medium/large varices or red wale signs

— TIPS for refractory ascites or variceal bleeding

— Paracentesis with albumin for large-volume drainage (>5 L)

Lung volume reduction:

Lung transplantation:

Liver transplantation:

Combined lung-liver transplant: rare, for dual end-stage disease

Procedural cirrhosis care:

HCC management: resection, ablation, TACE, transplant per BCLC staging

Step 3 management: A young (40s) PiZZ patient with progressive emphysema and declining FEV1 should be referred for transplant evaluation early—do not wait for FEV1 < 20%. Early referral is the right answer

CCS pearl: Order pulmonary rehab consult before considering surgical options—improves pre- and post-procedural outcomes and is a frequent test item

Special Populations — Elderly and Renal/Hepatic Impairment

— AAT often underdiagnosed—attributed to "ordinary COPD"; test if smoking history doesn't match severity or if basilar emphysema

— Augmentation therapy has no age cutoff but weigh functional status, comorbidities, life expectancy; benefit accrues over years

— Higher fall, fracture, and osteoporosis risk from chronic steroid bursts → DEXA scan, calcium/vitamin D, bisphosphonates as indicated

— Polypharmacy review: anticholinergic burden from LAMAs, sympathomimetic effects of LABAs in CAD

— Advance care planning essential, especially for transplant candidacy decisions

— AAT augmentation has no renal dose adjustment—plasma protein, no renal clearance issues

— Avoid nephrotoxic antibiotics during exacerbations; adjust aminoglycosides, vancomycin

— In AAT-associated C-ANCA vasculitis with glomerulonephritis, AAT replacement does not treat the vasculitis—immunosuppression (rituximab, cyclophosphamide + steroids) required

— Augmentation therapy is safe in liver disease (does not worsen accumulation; the issue is the patient's own misfolded protein, not exogenous functional protein)

— Avoid hepatotoxins: acetaminophen > 2 g/day, alcohol entirely, certain TB drugs, methotrexate

— Inhaled corticosteroids (fluticasone, budesonide) are largely safe; systemic steroids may worsen glucose, bone, BP in cirrhotic patients

— NSAIDs contraindicated in cirrhosis with ascites (precipitate HRS)

— Liver transplant evaluation when MELD ≥ 15 or decompensation; AAT patients prioritized appropriately

Elderly patients:

Renal impairment:

Hepatic impairment:

Board pearl: A liver donor's normal SERPINA1 corrects the recipient's deficiency—post-liver-transplant patients achieve normal serum AAT levels and can discontinue augmentation therapy. Frequently tested concept

Step 3 management: In a cirrhotic AAT patient with new pulmonary symptoms, distinguish hepatopulmonary syndrome (platypnea, orthodeoxia, contrast echo with intrapulmonary shunting) from progressive AAT emphysema—management is entirely different

Special Populations — Pregnancy, Pediatrics, and Family Screening

— Neonatal presentation: prolonged conjugated hyperbilirubinemia (>2 weeks), hepatomegaly, acholic stools — must distinguish from biliary atresia (surgical emergency requiring Kasai by 8 weeks)

— Workup: fractionated bilirubin, GGT, AAT level + phenotype, HIDA scan, abdominal ultrasound, liver biopsy if needed

— ~10–20% of PiZZ children develop significant liver disease; most have transient neonatal hepatitis that resolves

— Childhood/adolescent presentation: elevated transaminases, occasionally portal hypertension

— No augmentation therapy in children—lung disease is exceedingly rare before adulthood; augmentation is not FDA-approved < 18

— Pregnancy generally tolerated; severe emphysema or pulmonary hypertension elevates maternal mortality

— Augmentation therapy: limited data; generally continued if already on it with good outcomes; case-by-case

— Avoid teratogens: ACE inhibitors, ARBs, statins, warfarin, mycophenolate (if post-transplant)

— Vaccinations: influenza (inactivated), Tdap, COVID-19, RSV during pregnancy

— Genetic counseling for partner testing → fetal risk estimation

— First-degree relatives of probands should be offered AAT level + phenotype/genotype after counseling

— Identifies asymptomatic carriers (PiMZ) and homozygotes for early lifestyle modification

— GINA (Genetic Information Nondiscrimination Act) protects against health insurance and employment discrimination—but not life, disability, or long-term care insurance—disclose this in counseling

— Modestly increased COPD risk if smokers; lung disease in nonsmoking MZ is uncommon

— Small increase in liver disease risk, especially with co-existing NAFLD, alcohol, HCV

Pediatrics:

Pregnancy:

Family screening:

Carrier (PiMZ) considerations:

Board pearl: Neonatal cholestasis + normal HIDA + low serum AAT → AAT deficiency, not biliary atresia. PAS-D-positive globules confirm

Step 3 management: Offer genetic counseling before family testing—respect autonomy and informed consent

Complications and Adverse Outcomes

— Acute exacerbations of COPD (viral/bacterial triggers) with accelerated FEV1 decline

— Bronchiectasis with chronic Pseudomonas or nontuberculous mycobacteria colonization

— Spontaneous pneumothorax (bullae rupture)

— Chronic respiratory failure, type II (hypercapnic)

— Cor pulmonale and secondary pulmonary hypertension

— Increased lung cancer risk independent of smoking (modest)

— Cirrhosis with portal hypertension: varices, ascites, hepatic encephalopathy, SBP, HRS

— Hepatocellular carcinoma—elevated risk even without cirrhosis in PiZZ; surveillance critical

— Cholangiocarcinoma (rare association)

— Coagulopathy, hepatopulmonary syndrome, portopulmonary hypertension

— Necrotizing panniculitis: painful ulcerating nodules; responds dramatically to IV augmentation therapy (one of the clearest indications outside emphysema)

— C-ANCA/PR3 vasculitis (granulomatosis with polyangiitis): more severe disease and higher relapse rates in AAT-deficient patients

— Glomerulonephritis (rare), intracranial aneurysms (debated association)

— Augmentation: infusion reactions, rare anaphylaxis (IgA-deficient patients receiving IgA-containing product), theoretical infection transmission (extensively screened/processed)

— Long-term ICS: pneumonia, oral candidiasis, osteoporosis, cataracts

— Long-term azithromycin: QT prolongation, ototoxicity, macrolide resistance

— Depression, anxiety prevalent in chronic lung disease

— Caregiver burden, work disability, insurance navigation

Pulmonary complications:

Hepatic complications:

Extra-pulmonary/hepatic:

Treatment-related complications:

Psychosocial:

Key distinction: Panniculitis and PR3-vasculitis are the two non-pulmonary, non-hepatic manifestations on Step 3 buzzword lists—recognizing them in vignettes triggers AAT testing

Board pearl: HCC surveillance in AAT cirrhosis follows the standard 6-month ultrasound ± AFP protocol; missing surveillance is a frequent quality-metric question

When to Escalate — ICU, Consult, and Inpatient Triage

— Severe respiratory distress unresponsive to initial therapy

— Hypercapnic respiratory failure: pH < 7.25, PaCO₂ rising despite NIPPV

— Hemodynamic instability, altered mental status, exhaustion

— Need for invasive mechanical ventilation

— Failure of noninvasive positive pressure ventilation (NIPPV) trial after 1–2 hours

— Inadequate response to outpatient escalation

— Significant comorbidities (HF, pneumonia, new arrhythmia)

— Acute hypoxemia requiring more than baseline O₂

— Inability to manage at home (frailty, social factors)

— Pulmonology: all confirmed AAT cases for augmentation, registry enrollment, transplant timing

— Hepatology: any LFT abnormalities, elastography, HCC surveillance, transplant evaluation

— Genetics counselor: family screening

— Specialty pharmacy/social work: navigate augmentation therapy access, copay assistance (manufacturer programs, AlphaNet)

— Palliative care: advanced disease, symptom management, advance directives

— Transplant centers: dual evaluation for lung ± liver

— O₂ to target SpO₂ 88–92% (avoid over-oxygenation → CO₂ retention)

— Bronchodilators: nebulized albuterol + ipratropium q4–6h

— Systemic corticosteroids: prednisone 40 mg PO × 5 days (or methylprednisolone IV)

— Antibiotics if increased sputum purulence/volume or pneumonia: azithromycin, doxycycline, or amox-clav (5–7 days)

— NIPPV for hypercapnic respiratory failure with pH 7.25–7.35

— DVT prophylaxis, glucose monitoring on steroids

ICU triage criteria for AAT exacerbation:

Inpatient (non-ICU) admission:

Consultations:

Acute exacerbation management (CCS sequence):

CCS pearl: Order ABG (not just pulse ox) when considering NIPPV—pH and PaCO₂ drive the decision. Forgetting ABG is a recurrent CCS deduction

Step 3 management: Trial NIPPV before intubation in cooperative hypercapnic patients without contraindications—reduces mortality and length of stay

Key Differentials — Same-Category (Obstructive Lung Disease) Causes

— Apical/upper-lobe centrilobular emphysema

— Older age (60s+), heavy smoking history (≥20 pack-years)

— Normal AAT level

— No family history of early COPD

— Reversible airflow obstruction (≥12% and 200 mL FEV1 improvement post-bronchodilator)

— Eosinophilia, allergic phenotype, atopy

— Onset often in childhood; episodic symptoms

— Normal DLCO (vs. reduced in emphysema)

— Asthma-COPD overlap (ACO) can coexist with AAT—test if features atypical

— Cystic fibrosis (CFTR mutations, sweat chloride test, sinopulmonary disease + pancreatic insufficiency)

— Primary ciliary dyskinesia (situs inversus possible — Kartagener)

— Post-infectious (TB, pertussis, severe pneumonia)

— Immunodeficiency (CVID, X-linked agammaglobulinemia — measure immunoglobulins)

— ABPA (allergic bronchopulmonary aspergillosis—asthma + eosinophilia + central bronchiectasis + elevated IgE)

— Post-transplant, connective tissue disease, toxic inhalation

— Mosaic attenuation on expiratory CT

— Premenopausal women, thin-walled cysts diffusely, chylous effusions, renal angiomyolipomas

— Young smokers, upper-lobe cysts and nodules, BRAF V600E mutation

Tobacco-related COPD (the most important mimic):

Asthma:

Bronchiectasis (other etiologies):

Bronchiolitis obliterans:

Lymphangioleiomyomatosis (LAM):

Pulmonary Langerhans cell histiocytosis:

Key distinction: Basilar panacinar emphysema in a young nonsmoker = AAT; apical centrilobular emphysema in an old smoker = tobacco COPD; diffuse cystic lung disease in a young woman = LAM. The lobe and demographics are the discriminators

Board pearl: Always check DLCO to separate asthma (normal) from emphysematous processes (reduced)—high-yield PFT pattern question

Key Differentials — Other-Category Causes (Especially for Liver Disease)

— Viral hepatitis B and C: HBsAg, anti-HBc, HCV antibody + RNA

— Alcohol-associated liver disease: AST:ALT > 2:1, history

— NAFLD/MASLD: metabolic syndrome, imaging steatosis

— Autoimmune hepatitis: ANA, anti-smooth muscle, anti-LKM, elevated IgG; female predominance

— Primary biliary cholangitis: anti-mitochondrial antibody (AMA), elevated alkaline phosphatase, middle-aged women, pruritus

— Primary sclerosing cholangitis: p-ANCA, MRCP "beads on a string", associated IBD (UC)

— Hereditary hemochromatosis: HFE C282Y/H63D, ↑ ferritin, ↑ transferrin saturation > 45%, bronze diabetes, cardiomyopathy

— Wilson disease: low ceruloplasmin, ↑ 24-h urine copper, Kayser-Fleischer rings (slit lamp), neuropsychiatric symptoms; consider in patients < 40

— Drug-induced: methotrexate, amiodarone, isoniazid, valproate

— IV drug use (methylphenidate, talc granulomatosis): basilar emphysema mimic

— Marfan syndrome / Ehlers-Danlos: cystic lung disease, pneumothoraces

— Birt-Hogg-Dubé: lower-lobe cysts, renal tumors, skin fibrofolliculomas

— Cystic fibrosis (sinopulmonary + biliary cirrhosis)

— Sarcoidosis (pulmonary + hepatic granulomas)

— Hereditary hemorrhagic telangiectasia (pulmonary AVMs + liver involvement)

Cryptogenic cirrhosis workup (broad differential—AAT is one entity):

Pulmonary differentials for emphysema-like CT findings:

Combined pulmonary-hepatic syndromes:

Step 3 management: A cryptogenic cirrhosis workup is incomplete without an AAT level + phenotype—it's part of the standard panel along with viral, autoimmune, iron, and copper studies. Failing to include it is a tested error

Key distinction: Wilson disease and AAT deficiency are the two inherited causes of young-adult cryptogenic cirrhosis you must always include in the differential—ceruloplasmin + AAT level is the paired screen

Secondary Prevention, Discharge Medications, and Long-Term Plan

— LAMA + LABA ± ICS based on GOLD group and eosinophil count

— SABA PRN (albuterol MDI with spacer)

— Completion of prednisone 5-day course (no taper needed)

— Completion of antibiotic course if started

— Smoking cessation pharmacotherapy at discharge—do not defer to outpatient

— Continue IV augmentation therapy weekly if already initiated

— Home O₂ if qualifying ABG/SpO₂ criteria met (recheck in 60–90 days, since acute hypoxemia may resolve)

— Influenza (annual), pneumococcal (PCV20 or PCV15→PPSV23), COVID-19, RSV (age ≥ 60), Tdap, hepatitis A and B

— Statin per ASCVD risk

— DEXA scan; calcium 1,000–1,200 mg/day, vitamin D 800–1,000 IU/day, bisphosphonate if osteoporosis

— 6-month US ± AFP for HCC surveillance if cirrhotic

— EGD variceal screening at cirrhosis diagnosis; repeat per findings (every 1–3 years)

— Avoid alcohol entirely; counsel on hepatotoxin avoidance

— Hepatitis A and B vaccination if non-immune

— Home infusion vs. infusion center; specialty pharmacy coordination

— Insurance prior authorization, copay assistance via manufacturers and AlphaNet patient services

— Monitor for infusion reactions; check IgA pre-treatment if hypersensitivity history

Discharge medication checklist (post-exacerbation):

Vaccination catch-up at discharge if missed:

Cardiovascular and bone health:

Liver-specific long-term plan:

Augmentation therapy logistics:

Patient registry: enrollment in Alpha-1 Foundation Research Registry supports research and connects patients to resources

Step 3 management: Always rebook a 4–8 week post-discharge visit with PFTs and symptom assessment; reassess oxygen need at 60–90 days. Both are testable transition-of-care items

Board pearl: Hepatitis A and B vaccination is especially crucial in AAT patients with any liver involvement—superimposed viral hepatitis can precipitate decompensation

Follow-Up, Monitoring, and Rehabilitation

— Stable mild disease: every 6–12 months

— Moderate-severe disease: every 3–6 months

— On augmentation: weekly infusion visits (home or center); quarterly clinical review

— Post-exacerbation: 4–8 week visit, then quarterly

— Spirometry annually (more often if declining)—FEV1 trajectory is the key pulmonary metric

— DLCO every 1–2 years

— 6-minute walk test annually or with symptom change

— HRCT chest every 2–5 years or for new symptoms (densitometry in research/registry settings)

— ABG when SpO₂ < 92% or hypercapnia suspected

— CBC, BMP, LFTs at least annually

— Liver elastography every 1–3 years; ultrasound + AFP every 6 months if cirrhotic

— Echocardiogram every 1–2 years to screen for pulmonary hypertension in advanced disease

— Indicated for mMRC ≥ 2, recent exacerbation, or functional limitation

— 8–12 week structured program: exercise training, education, nutrition, psychosocial support

— Improves quality of life, exercise tolerance, reduces hospitalizations

— Maintenance program post-completion critical for sustained benefit

— Smoking cessation reinforcement at every visit (5 A's: Ask, Advise, Assess, Assist, Arrange)

— Trigger avoidance: dust, fumes, biomass, wildfire smoke (N95 in poor AQI)

— Inhaler technique re-demonstration—poor technique is rampant

— Medication adherence, side effect monitoring

— Action plan for exacerbations (when to start rescue prednisone/antibiotics, when to call/seek care)

— Mental health screening (PHQ-9, GAD-7) annually

Follow-up cadence:

Monitoring parameters:

Pulmonary rehabilitation:

Counseling priorities:

CCS pearl: Order inhaler technique demonstration at follow-up—poor technique is a tested cause of "treatment failure"

Step 3 management: Refer to pulmonary rehab even in moderate disease—it's underused and frequently the right answer when offered as an option

Ethical, Legal, and Patient Safety Considerations

— Informed consent for AAT phenotype/genotype must include: implications for the patient, insurance and employment implications, family member risk, and reproductive considerations

— GINA (2008) prohibits health insurance and employment discrimination based on genetic information but does NOT cover life, disability, or long-term care insurance—a critical disclosure

— Pre-test counseling preferred, especially before cascade testing of asymptomatic relatives

— Pediatric testing of asymptomatic children is generally deferred until adulthood unless clinically indicated, respecting future autonomy

— Preimplantation genetic diagnosis and prenatal testing available for known PiZZ couples

— Nondirective counseling—patient/couple values guide decisions

— Pediatric-to-adult transition in PiZZ patients with childhood liver disease is high-risk for loss to follow-up

— Structured transition clinics with warm handoff to adult hepatology/pulmonology

— Medication reconciliation at every transition (admission, discharge, specialty handoff) — augmentation therapy continuity especially

— Infusion safety: verify product, dose, IgA status if reaction history; resuscitation capability on-site

— Polypharmacy in elderly: anticholinergic LAMAs + sedatives ↑ delirium risk

— Oxygen safety counseling: no smoking in home, secured tanks, fire risk

— NIPPV in hypercapnia: monitor pH/PCO₂; avoid in altered mental status without airway protection

— Augmentation therapy cost ~$100,000/year—prior authorization, appeals, copay assistance navigation

— Equity considerations: AAT is underdiagnosed in non-white populations and in resource-limited regions

— Long-term O₂ does not preclude driving but requires accommodations

— Disability paperwork for severe disease; physician role in honest, accurate documentation

Genetic testing and counseling:

Reproductive ethics:

Transition of care risks:

Patient safety:

Resource allocation and access:

Driving and disability:

Board pearl: GINA protections apply to health insurance + employment ONLY—life, disability, and long-term care insurance can still consider genetic information. This is the single most testable AAT ethics item

Step 3 management: Document informed consent for AAT testing, including the GINA caveat, in the chart—it's a quality-and-safety expectation

High-Yield Associations and Rapid-Fire Clinical Facts

Gene: SERPINA1, chromosome 14q32.13, codominant inheritance

Most common severe genotype: PiZZ (Glu342Lys); ~95% of clinically severe cases

PiMZ: carrier, modest risk only with smoking or co-existing liver insults

Threshold for protection: serum AAT > 11 µmol/L (57 mg/dL)

Lung pathology: panacinar emphysema, lower-lobe predominant

Liver pathology: PAS-positive, diastase-resistant intrahepatocyte globules

Skin association: necrotizing panniculitis — responds to augmentation therapy

Vasculitis association: C-ANCA/PR3 (granulomatosis with polyangiitis)

Imaging buzzword: basilar bullae on CT in a young nonsmoker

Therapy: weekly IV pooled human alpha-1 proteinase inhibitor 60 mg/kg

Augmentation indication: PiZZ/null with emphysema, FEV1 ~30–65%, non/ex-smoker

No medical therapy for liver disease—augmentation does not treat liver

Liver transplant corrects AAT deficiency; lung transplant does not

Smoking accelerates lung disease by decades; alcohol accelerates liver disease

HCC surveillance: US ± AFP every 6 months if cirrhotic

Screening recommendation (GOLD/ATS/ERS): test all symptomatic COPD patients once

Family screening: first-degree relatives, after counseling

GINA: protects health insurance and employment, not life/disability/long-term care

RAPID trial: showed slowed CT lung density loss with augmentation

AAT is an acute-phase reactant: levels rise with inflammation; always confirm with phenotype

Diagnostic delay: average 5–7 years from symptom onset

Trio of "young + nonsmoker + basal emphysema" = test immediately

Wilson + AAT = paired tests in cryptogenic cirrhosis under age 50

Board pearl: When a stem mentions panniculitis or PR3-vasculitis in an emphysema patient, AAT testing is the answer

Key distinction: PiZZ + emphysema → augmentation; PiZZ + cirrhosis → transplant evaluation. Different organs, different definitive therapies, but smoking/alcohol cessation applies to both

Board Question Stem Patterns

— 38-year-old never-smoker, progressive dyspnea, basilar emphysema on CT

— Next step: serum AAT level + phenotype

— Best long-term therapy: smoking avoidance + augmentation (if FEV1 30–65%)

— 45-year-old with cirrhosis, negative viral and autoimmune workup

— Next step: AAT level, ceruloplasmin, iron studies

— Liver biopsy shows PAS-positive diastase-resistant globules → AAT deficiency

— 6-week-old with persistent jaundice, conjugated hyperbilirubinemia, acholic stools

— Differential includes biliary atresia (Kasai-eligible window!) vs. AAT deficiency

— Next step: HIDA, abdominal US, AAT level + phenotype

— Father with PiZZ, asks about testing his children

— Answer: genetic counseling first, then test first-degree relatives

— Newly diagnosed PiZZ with FEV1 45% predicted, ex-smoker

— Answer: weekly IV alpha-1 proteinase inhibitor 60 mg/kg

— Painful ulcerating skin nodules + history of emphysema

— Diagnosis: AAT deficiency; treat with augmentation

— PiZZ patient post-OLT; question asks about continued augmentation

— Answer: discontinue—donor liver produces normal AAT

— Obstructive PFTs + reduced DLCO in a 40-year-old → emphysema → suspect AAT

— Basilar emphysema differentiates AAT from typical apical COPD

— AAT level "borderline" during pneumonia—next step is repeat after recovery + phenotype regardless

— Counseling before genetic test; what protections apply

— Answer: health insurance + employment, not life/disability

— Cirrhotic AAT patient: US + AFP every 6 months

Pattern 1 — The young nonsmoker with COPD:

Pattern 2 — Cryptogenic cirrhosis:

Pattern 3 — Neonatal cholestasis:

Pattern 4 — Family screening:

Pattern 5 — Augmentation therapy logistics:

Pattern 6 — Necrotizing panniculitis:

Pattern 7 — Post-liver-transplant AAT:

Pattern 8 — Pulmonary function pattern:

Pattern 9 — Lobe distribution:

Pattern 10 — Acute-phase confounding:

Pattern 11 — GINA disclosure:

Pattern 12 — HCC surveillance:

Step 3 management: When in doubt on AAT vignettes, the right answer almost always involves serum AAT level + phenotype, smoking cessation, and specialist referral—the diagnostic-management triad

Board pearl: Necrotizing panniculitis is the single most pathognomonic skin finding for AAT deficiency on boards

One-Line Recap

High-yield bullet recaps:

Alpha-1 antitrypsin deficiency is an autosomal codominant SERPINA1 disorder (classically PiZZ) that causes early-onset basilar panacinar emphysema from unopposed neutrophil elastase and adult cryptogenic cirrhosis with hepatocellular carcinoma risk from intrahepatic Z-protein polymerization, diagnosed by serum AAT level + phenotype/genotype and treated with smoking cessation, GOLD-guided inhaler therapy, weekly IV alpha-1 proteinase inhibitor augmentation for qualifying lung disease, and transplantation for end-stage organ failure.

Test once in every symptomatic COPD patient (GOLD/ATS/ERS); basilar emphysema in a young nonsmoker is the classic trigger

PAS-positive, diastase-resistant globules in periportal hepatocytes are pathognomonic on liver biopsy; panacinar lower-lobe emphysema is the pulmonary signature

Augmentation therapy (60 mg/kg IV weekly) treats the lung, not the liver; liver transplant corrects the genetic defect while lung transplant does not

Don't miss necrotizing panniculitis and C-ANCA/PR3 vasculitis as extrapulmonary clues that should trigger AAT testing

Smoking cessation is the single highest-impact intervention—more important than any drug, asked at every visit, and the right Step 3 answer whenever offered

HCC surveillance every 6 months with ultrasound ± AFP in any AAT patient with cirrhosis

GINA protects health insurance and employment during genetic testing counseling—not life, disability, or long-term care insurance

Family cascade screening of first-degree relatives is appropriate after genetic counseling; defer asymptomatic pediatric testing when feasible to preserve future autonomy

Board pearl: "Young, nonsmoker, basal emphysema, cryptogenic cirrhosis, panniculitis, PR3-vasculitis"—any one of these in a stem should trigger an AAT level + phenotype as the next diagnostic step, and augmentation + smoking cessation + transplant referral as the management triad